醫療器械板塊走弱 冠脈支架國家集採價格降至千元以下
格隆匯11月6日丨醫療器械板塊走弱,心脈醫療跌超15%領跌,大博醫療、凱利泰跌超9%,藍帆醫療、賽諾醫療、振德醫療等紛紛下跌。

昨日,由國家組織的首次高值醫用耗材冠脈支架集中帶量採購工作在天津進行。從中標價格來看,擬中選價格中位數約700 元,低於此前市場預期的千元左右價格,入圍產品價格相比2019 年終端掛網價降幅基本在90%-96%之間,也顯著低於2850 元的保護價。
平安證券表示,經過此次不分組、價格主導的冠脈支架帶量採購,國家降低高值耗材價格的決心已經非常明顯,市場不應對後續其他高值耗材產品的降幅抱有太高預期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.